抗菌剤市場：タイプ別、薬剤クラス別、グレード別、剤形別、流通チャネル別、地域別、機会、予測、2018年～2032年

世界の抗菌剤の市場規模は、2025年～2032年の予測期間中に4.70%のCAGRで拡大し、2024年の456億7,000万米ドルから2032年には659億5,000万米ドルに成長すると予測されています。

抗菌剤の発見は、採用された技術革新によって様々な分野に徐々に利益をもたらしています。組み込まれた抗菌剤は、属するグループによって特有の特性を発揮します。タンパク質、細胞壁、核酸の合成を阻害し、細胞膜を脱分極させ、バクテリアの代謝経路を阻害するといった特異的なメカニズムです。抗菌ペプチドは、負に帯電したリン脂質と適切に相互作用することで、微生物の細胞膜を破壊し、抗菌活性または抗がん活性を付与する可能性があります。抗菌剤は農業食品部門に広く関与しており、それが不用意な使用の原因となっており、耐性菌への顕著な寄与が健康上の緊急事態への懸念を薄れさせています。

当レポートでは、世界の抗菌剤市場について調査し、市場の概要とともに、タイプ別、薬剤クラス別、グレード別、剤形別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の抗菌剤市場の見通し、2018年～2032年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2024年
  • タイプ別
  • 薬剤クラス別
  • グレード別
  • 剤形別
  • 流通チャネル別
  • 地域別

第5章 北米の抗菌剤市場の見通し、2018年～2032年

第6章 欧州の抗菌剤市場の見通し、2018年～2032年

第7章 アジア太平洋の抗菌剤市場の見通し、2018年～2032年

第8章 南米の抗菌剤市場の見通し、2018年～2032年

第9章 中東・アフリカの抗菌剤市場の見通し、2018年～2032年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 ケーススタディ

第19章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要参入企業トップ10の情勢
  • AstraZeneca plc
  • AbbVie, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.

第20章 戦略的提言

第21章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 3. Global Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 4. Global Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 5. Global Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 6. Global Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 7. Global Antimicrobials Market Share (%), By Region, 2018-2032F
• Figure 8. North America Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 9. North America Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 10. North America Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 11. North America Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 12. North America Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 13. North America Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 14. North America Antimicrobials Market Share (%), By Country, 2018-2032F
• Figure 15. United States Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 16. United States Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 17. United States Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 18. United States Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 19. United States Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 20. United States Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 21. Canada Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 22. Canada Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 23. Canada Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 24. Canada Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 25. Canada Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 26. Canada Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 27. Mexico Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 28. Mexico Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 29. Mexico Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 30. Mexico Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 31. Mexico Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 32. Mexico Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 33. Europe Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 34. Europe Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 35. Europe Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 36. Europe Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 37. Europe Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 38. Europe Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 39. Europe Antimicrobials Market Share (%), By Country, 2018-2032F
• Figure 40. Germany Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 41. Germany Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 42. Germany Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 43. Germany Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 44. Germany Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 45. Germany Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 46. France Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 47. France Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 48. France Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 49. France Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 50. France Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 51. France Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 52. Italy Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 53. Italy Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 54. Italy Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 55. Italy Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 56. Italy Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 57. Italy Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 58. United Kingdom Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 59. United Kingdom Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 60. United Kingdom Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 61. United Kingdom Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 62. United Kingdom Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 63. United Kingdom Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 64. Russia Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 65. Russia Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 66. Russia Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 67. Russia Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 68. Russia Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 69. Russia Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 70. Netherlands Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 71. Netherlands Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 72. Netherlands Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 73. Netherlands Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 74. Netherlands Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 75. Netherlands Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 76. Spain Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 77. Spain Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 78. Spain Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 79. Spain Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 80. Spain Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 81. Spain Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 82. Turkey Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 83. Turkey Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 84. Turkey Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 85. Turkey Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 86. Turkey Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 87. Turkey Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 88. Poland Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 89. Poland Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 90. Poland Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 91. Poland Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 92. Poland Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 93. Poland Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 94. South America Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 95. South America Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 96. South America Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 97. South America Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 98. South America Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 99. South America Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 100. South America Antimicrobials Market Share (%), By Country, 2018-2032F
• Figure 101. Brazil Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 102. Brazil Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 103. Brazil Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 104. Brazil Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 105. Brazil Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 106. Brazil Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 107. Argentina Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 108. Argentina Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 109. Argentina Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 110. Argentina Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 111. Argentina Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 112. Argentina Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 113. Asia-Pacific Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 114. Asia-Pacific Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 115. Asia-Pacific Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 116. Asia-Pacific Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 117. Asia-Pacific Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 118. Asia-Pacific Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 119. Asia-Pacific Antimicrobials Market Share (%), By Country, 2018-2032F
• Figure 120. India Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 121. India Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 122. India Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 123. India Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 124. India Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 125. India Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 126. China Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 127. China Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 128. China Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 129. China Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 130. China Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 131. China Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 132. Japan Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 133. Japan Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 134. Japan Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 135. Japan Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 136. Japan Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 137. Japan Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 138. Australia Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 139. Australia Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 140. Australia Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 141. Australia Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 142. Australia Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 143. Australia Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 144. Vietnam Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 145. Vietnam Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 146. Vietnam Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 147. Vietnam Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 148. Vietnam Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 149. Vietnam Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 150. South Korea Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 151. South Korea Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 152. South Korea Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 153. South Korea Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 154. South Korea Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 155. South Korea Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 156. Indonesia Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 157. Indonesia Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 158. Indonesia Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 159. Indonesia Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 160. Indonesia Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 161. Indonesia Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 162. Philippines Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 163. Philippines Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 164. Philippines Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 165. Philippines Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 166. Philippines Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 167. Philippines Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 168. Middle East & Africa Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 169. Middle East & Africa Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 170. Middle East & Africa Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 171. Middle East & Africa Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 172. Middle East & Africa Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 173. Middle East & Africa Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 174. Middle East & Africa Antimicrobials Market Share (%), By Country, 2018-2032F
• Figure 175. Saudi Arabia Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 176. Saudi Arabia Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 177. Saudi Arabia Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 178. Saudi Arabia Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 179. Saudi Arabia Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 180. Saudi Arabia Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 181. UAE Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 182. UAE Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 183. UAE Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 184. UAE Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 185. UAE Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 186. UAE Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 187. South Africa Antimicrobials Market, By Value, In USD Billion, 2018-2032F
• Figure 188. South Africa Antimicrobials Market Share (%), By Type, 2018-2032F
• Figure 189. South Africa Antimicrobials Market Share (%), By Drug Class, 2018-2032F
• Figure 190. South Africa Antimicrobials Market Share (%), By Grade, 2018-2032F
• Figure 191. South Africa Antimicrobials Market Share (%), By Dosage Form, 2018-2032F
• Figure 192. South Africa Antimicrobials Market Share (%), By Distribution Channel, 2018-2032F
• Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 194. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 195. By Grade Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 196. By Dosage Form Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global antimicrobials market is projected to witness a CAGR of 4.70% during the forecast period 2025-2032, growing from USD 45.67 billion in 2024 to USD 65.95 billion in 2032.

The discovery of antimicrobials has benefited various sectors progressively with the adopted innovations. The incorporated antimicrobials deliver specific characteristics based on the group they belong to. Specific mechanisms, such as inhibiting protein, cell wall, and nuclei acid synthesis, depolarize the cell membrane and inhibit metabolic pathways in bacteria. Antimicrobial peptides have the potential to impart either antimicrobial or anticancer activities that subsequently disrupt microbial cell membranes by making proper interaction with negatively charged phospholipids. Antimicrobials have extensive involvement in the agri-food sector, which is responsible for imprudent use, and their prominent contribution to resistance can diminish the concerns for health emergencies.

Adoption of Regulations Boosting Market Growth

The numerous benefits of antimicrobial agents can be recognized across various sectors, including health treatments. Despite several advantages, inappropriate usage of antimicrobial agents within healthcare facilities can decisively lead to the acquisition of nosocomial infections, drug toxicity, unwanted resistance build-up, etc. The World Health Organization (WHO) has framed effective regulations on different quantities and combinations for using antimicrobial agents in pharmaceuticals. Fixed doses of antimicrobial combinations can be banned if not approved by national or international guidelines. Stringent legislation has been implemented functionally, regulating the antimicrobials prescribed by qualified healthcare professionals. Several antimicrobial awareness campaigns, such as World Antibiotic Awareness Week held in November each year between the dates 8-14 by the World Health Organization (WHO) and similar relevant campaigns, are frequently organized to address the benefits of antimicrobials and their consumption in the prescribed form. Scientifically validated clinical studies have been provided with specific regulations to justify the choice and level of antimicrobial agents to be incorporated in health-related applications. For instance, in January 2024, to limit the misuse of antimicrobial drugs, the Central Government of India announced that it is mandatory for all doctors to write 'exact indications' while prescribing these drugs.

Growing Incidences of Infectious Diseases to Fuel Market Growth

One of the key factors propelling the global antimicrobial industry and greatly impacting its growth trajectory is the rising prevalence of infectious diseases. The need for efficient antimicrobial therapies has increased due to the rise of illnesses, including HIV, malaria, tuberculosis, and other bacterial infections. The prevalence of infectious diseases is increasing due to several variables. Increased international travel and urbanization speed up the spread of diseases, and climate change fosters an environment that is conducive to the spread of diseases. For instance, according to the WHO Global Tuberculosis Report 2024, around 10.8 million people have been diagnosed with TB globally. The report further stated that India, Indonesia, China, the Philippines, and Pakistan together accounted for 56% of the total global burden.

Furthermore, the problem has been worsened by the lack of proper healthcare infrastructure in underdeveloped nations, which makes it difficult to control outbreaks efficiently. The COVID-19 pandemic increased the need for efficient infection control methods and brought attention to weaknesses in healthcare systems. In order to fight these infections, there is a constant need for novel and enhanced antimicrobial drugs. The continuous demand for potent antimicrobial remedies not only propels market expansion but also stimulates pharmaceutical industry innovation, resulting in the creation of innovative therapies that can successfully combat new pathogenic threats.

Antibacterial Drug Segment Dominates the Market

The growing incidence of bacterial infections and the growing need for efficient treatment alternatives have propelled the antibacterials segment to the top of the global antimicrobial market. Since they are widely used to treat a variety of illnesses, including respiratory and urinary tract infections, antibacterials-in particular, penicillin and cephalosporins-dominate this market category. Due to its proven use in both developed and developing nations, as well as its efficacy against a wide range of bacterial infections, the penicillin category alone accounted for a sizeable portion of the market. Furthermore, research and development attempts to produce more effective antibacterial agents have been sparked by the increased knowledge of antibiotic resistance. Novel formulations and delivery systems are being researched to improve efficacy against resistant strains. For instance, in November 2024, the Biotechnology Industry Research Assistance Council (BIRAC), a unit of the Department of Biotechnology in collaboration with Wockhardt Ltd., introduced India's first indigenous Nafithromycin antibiotic to treat resistant infections. The antibiotic has been launched under the trade name "Miqnaf" by Wockhardt Ltd. The company has invested around 14 years and USD 65 million (INR 550 crores) into research and development of Nafithromycin, with clinical trials spanning the U.S., Europe, and India.

Antibacterials are still mostly consumed by the healthcare industry, which uses them widely in clinics and hospitals to prevent and treat infections. Antibacterial demand is predicted to increase further as healthcare infrastructure worldwide, particularly in emerging nations, improves. This pattern highlights the significance of antibacterials in the antimicrobial market as a whole, making them a key area of concentration for pharmaceutical firms looking to address public health issues successfully.

North America Holds the Dominant Share in Antimicrobials Market

The global antimicrobial market is dominated by North America, which greatly impacts its expansion and advancement. Numerous reasons contribute to this supremacy, such as the region's sophisticated healthcare infrastructure and large investments in research and development of novel antimicrobial medicines. For Instance, in the U.S., influenza and pneumonia caused 41,917 deaths in 2022, according to the Centers for Disease Control and Prevention. This concerning figure highlights the urgent need for potent antimicrobial medicines and cutting-edge therapies, which will increase market demand. Furthermore, the United States enjoys the advantages of a strong regulatory environment that facilitates drug approval procedures and motivates pharmaceutical firms to create novel antibiotics and substitutes. Campaigns for safe antibiotic use have been sparked by growing public knowledge of antibiotic resistance and the negative effects of abuse. Major companies actively working on creating new treatments to fight resistant bacterial strains are also part of the pharmaceutical industry in the United States. As a result, the United States is a key factor in the future expansion of this industry since it not only holds a dominant market share but also plays a significant role in influencing worldwide antimicrobial tactics and advancements.

Future Market Scenario (2025-2032F)

Technological advancements like PCR promise faster and more accurate results, leading us to the early diagnosis of the disease. Opportunity also lies in the increasing number of viral infections the globe faces today. Developing vaccines or a cure for diseases that are still not curable is a challenge that the whole healthcare community is facing at the moment. Promising moves of governments in their countries that provide healthcare infrastructure, funds to carry on research and development on a large scale, and a reliable distribution channel that ensures the solution reaches everyone is testimonial. For instance, in India, the Infectious Disease Biology Program aims to provide solutions to infectious diseases of global concern such as HIV/AIDS, tuberculosis, vector-borne diseases; emerging or re-emerging threats such as influenza, Japanese Encephalitis, and antibiotic-resistant microbes in terms of therapeutics, diagnostics, and preventive measures. The Program supports R&D projects to achieve the Sustainable Development Goals of ending the epidemics of AIDS, TB, malaria, and neglected tropical diseases and combat hepatitis, water-borne diseases, and other communicable diseases by 2030.

Key Players Landscape and Outlook

Key players in the antimicrobials industry are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

In May 2023, Innoviva Specialty Therapeutics Inc. got FDA approval for XACDURO (durlobactam for injection; sulbactam for injection), co-packaged for intravenous use.

For instance, in April 2023, Baxter International Inc. launched ZOSYN in the United States (piperacillin and tazobactam) Injection.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Antimicrobials Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Antibacterial
    • 4.2.1.2. Antifungal
    • 4.2.1.3. Antiviral
    • 4.2.1.4. Others
  • 4.2.2. By Drug Class
    • 4.2.2.1. Penicillin
    • 4.2.2.2. Cephalosporin
    • 4.2.2.3. Aminoglycosides
    • 4.2.2.4. Fluoroquinolones
    • 4.2.2.5. Others
  • 4.2.3. By Grade
    • 4.2.3.1. Natural
    • 4.2.3.2. Semi-Synthetic
    • 4.2.3.3. Synthetic
  • 4.2.4. By Dosage Form
    • 4.2.4.1. Powder
    • 4.2.4.2. Tablet
    • 4.2.4.3. Solution
    • 4.2.4.4. Liquid
    • 4.2.4.5. Others
  • 4.2.5. By Distribution Channel
    • 4.2.5.1. Hospital Pharmacy
    • 4.2.5.2. Retail Pharmacy
    • 4.2.5.3. Online Pharmacy
  • 4.2.6. By Region
    • 4.2.6.1. North America
    • 4.2.6.2. Europe
    • 4.2.6.3. Asia-Pacific
    • 4.2.6.4. South America
    • 4.2.6.5. Middle East and Africa
  • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Grade
  • 4.3.4. By Dosage Form
  • 4.3.5. By Distribution Channel
  • 4.3.6. By Region

5. North America Antimicrobials Market Outlook, 2018-2032F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Antibacterial
    • 5.2.1.2. Antifungal
    • 5.2.1.3. Antiviral
    • 5.2.1.4. Others
  • 5.2.2. By Drug Class
    • 5.2.2.1. Penicillin
    • 5.2.2.2. Cephalosporin
    • 5.2.2.3. Aminoglycosides
    • 5.2.2.4. Fluoroquinolones
    • 5.2.2.5. Others
  • 5.2.3. By Grade
    • 5.2.3.1. Natural
    • 5.2.3.2. Semi-Synthetic
    • 5.2.3.3. Synthetic
  • 5.2.4. By Dosage Form
    • 5.2.4.1. Powder
    • 5.2.4.2. Tablet
    • 5.2.4.3. Solution
    • 5.2.4.4. Liquid
    • 5.2.4.5. Others
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Hospital Pharmacy
    • 5.2.5.2. Retail Pharmacy
    • 5.2.5.3. Online Pharmacy
  • 5.2.6. By Country Share
    • 5.2.6.1. United States
    • 5.2.6.2. Canada
    • 5.2.6.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Antimicrobials Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Type
        • 5.3.1.2.1.1. Antibacterial
        • 5.3.1.2.1.2. Antifungal
        • 5.3.1.2.1.3. Antiviral
        • 5.3.1.2.1.4. Others
      • 5.3.1.2.2. By Drug Class
        • 5.3.1.2.2.1. Penicillin
        • 5.3.1.2.2.2. Cephalosporin
        • 5.3.1.2.2.3. Aminoglycosides
        • 5.3.1.2.2.4. Fluoroquinolones
        • 5.3.1.2.2.5. Others
      • 5.3.1.2.3. By Grade
        • 5.3.1.2.3.1. Natural
        • 5.3.1.2.3.2. Semi-Synthetic
        • 5.3.1.2.3.3. Synthetic
      • 5.3.1.2.4. By Dosage Form
        • 5.3.1.2.4.1. Powder
        • 5.3.1.2.4.2. Tablet
        • 5.3.1.2.4.3. Solution
        • 5.3.1.2.4.4. Liquid
        • 5.3.1.2.4.5. Others
      • 5.3.1.2.5. By Distribution Channel
        • 5.3.1.2.5.1. Hospital Pharmacy
        • 5.3.1.2.5.2. Retail Pharmacy
        • 5.3.1.2.5.3. Online Pharmacy
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Antimicrobials Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Turkey
• 6.9. Poland

7. Asia-Pacific Antimicrobials Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Antimicrobials Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Antimicrobials Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Regulatory Approvals
• 17.2. Clinical Trials

18. Case Studies

19. Competitive Landscape

• 19.1. Competition Matrix of Top 5 Market Leaders
• 19.2. SWOT Analysis for Top 5 Players
• 19.3. Key Players Landscape for Top 10 Market Players
  • 19.3.1. AstraZeneca plc
    • 19.3.1.1. Company Details
    • 19.3.1.2. Key Management Personnel
    • 19.3.1.3. Products and Services
    • 19.3.1.4. Financials (As Reported)
    • 19.3.1.5. Key Market Focus and Geographical Presence
    • 19.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 19.3.2. AbbVie, Inc.
  • 19.3.3. Novartis AG
  • 19.3.4. Pfizer Inc.
  • 19.3.5. Bristol-Myers Squibb Company
  • 19.3.6. Eli Lilly and Company
  • 19.3.7. GlaxoSmithKline plc
  • 19.3.8. Merck & Co., Inc.
  • 19.3.9. F. Hoffmann-La Roche Ltd
  • 19.3.10. Teva Pharmaceutical Industries Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

20. Strategic Recommendations

21. About Us and Disclaimer